Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LARS1 | Q9P2J5 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25166481 | 0.85 | MEN1 (0.36) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL30329800 | 0.85 | MEN1 (0.36) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL25166256 | 0.79 | MAPT (0.37) | MAPTALDH1A1GAATDP1L3MBTL1 | |
| SCHEMBL30329719 | 0.78 | MAPT (0.40) | MAPTALDH1A1GAATDP1L3MBTL1 | |
| SCHEMBL25166010 | 0.76 | PARP1 (0.42) | — | |
| SCHEMBL25166593 | 0.74 | PARP1 (0.34) | MAPTALDH1A1GAAL3MBTL1MEN1 | |
| SCHEMBL21603395 | 0.72 | HPGD (0.36) | MAPTALDH1A1GAATDP1L3MBTL1 | |
| SCHEMBL30329662 | 0.71 | MAPT (0.49) | MAPTALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL31520283 | 0.71 | MAPT (0.41) | MAPTALDH1A1GAAKDM4E | |
| SCHEMBL17132321 | 0.71 | MAPT (0.41) | MAPTGAATDP1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. | 2024-11-07 | — | — | US | disclosed |
| CN-118647610-A | Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof | 探戈医药股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| WO-2023064586-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | TANGO THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368139-A1 | NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF | EHMT1, EHMT2, SHMT1 | MAPT 2171/4885ALDH1A1 163/4885GAA 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.